glp 1 kaiser coverage glp-1 permanente π Starting January 1, 2025, Kaiser Permanente will be making adjustments to the of GLP-1 drugs and other Anti-Obesity Medications (AOMs) in California commercial Nutritional priorities to support GLP-1
Description
We intervene early with nutrition, movement, and scientifically grounded therapies to restore health, vitality, and resilience
Keep scrolling for more health stories
Compounded versions are also unlawful
However, potential adverse mental health effects have also been reported and require vigilance: Nausea and gastrointestinal symptoms , common side effects of GLP-1 medications, may increase anxiety in susceptible individuals Rapid weight loss can occasionally trigger psychological distress or exacerbate eating disorder behaviours Mood changes , including low mood, have been reported in post-marketing surveillance, though causality remains uncertain Some patients report feeling emotionally flat or detached , though this is anecdotal and not well characterised in clinical trials The Summary of Product Characteristics (SmPC) for GLP-1 receptor agonists used for weight management (such as Saxenda and Wegovy) includes specific warnings about monitoring for mood disorders and suicidal thoughts
In the 72-week SURMOUNT-1 trial summarised in Mounjaros Australian product information, average weight change ranged from -16.0% to -22.5% depending on dose, versus -2.4% with placebo
GLP-1 stimulates cell proliferation in pancreatic ductal cells and islets, and exerts antiapoptotic actions on islet -cells and neurons
